Search

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Jun 12 2015 Posted in Press releases

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

EHA Bilateral Collaborative Grant review and selection process

1. Eligibility checkAfter the deadline has passed, we'll check your application for completion and compliance with the eligibility criteria.

EHA-ASH Translational Research Training in Hematology

TRTH 2025 call is now closed. What is Translational Research Training in Hematology?Translational Research Training in Hematology (TRTH) provides early-career researchers with a unique, year-long training and mentoring experience.

Policy on double awarding

We want to support as many young investigators and clinicians as possible in their career development. For this reason, we do not allow ‘double awarding.

Policy on double awarding

We want to support as many young investigators and clinicians as possible in their career development. For this reason, we do not allow ‘double awarding.

Policy on double awarding

We want to support as many young investigators and clinicians as possible in their career development. For this reason, we do not allow ‘double awarding.